Isotechnika, Inc.

Isotechnika, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Its lead compound includes ISA247, a calcineurin inhibitor, which is in European/Canadian Phase 3 clinical trial for the treatment of psoriasis; Phase 2b trial for the prevention of kidney rejection and transplantation; and Phase 2/Phase 3 trials for the treatment of uveitis. The company is also developing TAFA93, a small molecule mTOR inhibitor, which is used in the prevention of organ rejection following transplantation, in the treatment of autoimmune and oncological diseases that include ocular diseases, and as a component of coated stents for the treatment of coronary artery disease. In addition, it develops and sells a non-radioactive diagnostic breath test kit called Helikit worldwide, as well as Diatest, a diagnostic breath test kit that is used to investigate insulin resistance. The company has strategic collaboration with F. Hoffmann-La Roche and Hoffmann-La Roche, Inc. for the co-development and commercialization of ISA247; distribution and license agreement with Lux Biosciences, Inc. to develop and commercialize ISA247; licensing agreement with Atrium Medical Corporation for the use of TAFA93 and ISA247 with drug-eluting medical devices; and research and option agreement with Cellgate, Inc. Isotechnika was founded in 1993 and is headquartered in Edmonton, Canada.